Review Article Treating the Central Retinal Vein Occlusion: The Latest Option

After diabetic retinopathy, central retinal vein occlusion (CRVO) is the most common visually disabling disease affecting the retina. CRVO is caused by obstruction of the central retinal vein that leads to a backup of blood and fluid in the retina. This causes retinal damage and loss of vision. Release of vascular endothelial growth factor (VEGF) contributes to increased vascular permeability in the eye and macular edema. It is believed that anti-VEGF treatment may help decrease vascular permeability and edema in the retina in patients with CRVO. EYLEA (Regeneron Pharmaceuticals) is the latest anti-VEGF agent received FDA approval for the treatment of CRVO.The goal of this review is to evaluate the therapeutic potential of EYLEA in the management of CRVO